Table 2.
probe drug | PBPK model | absorbed × intestinal availability, FaFg | absorption rate constant, ka (1/h) | distribution volume, V1 (L) | hepatic intrinsic clearance, CLh,int, in vivo (L/h) | hepatic clearance, CLh (L/h) | AUClast, ng h−1 mL−1 |
---|---|---|---|---|---|---|---|
caffeine | human, from humanized mice | 1 | 0.50 | 18.6 | 4.91 | 4.35 | 26200 |
human, average (± SD) | 1 | 0.97 (± 0.57) | 58.1 (± 29.4) | 7.25 (± 1.71) | 4.83 (± 2.52) | 16700 (± 6000) | |
literature | 21,300 (± 9,530) | ||||||
S-warfarin | human, from humanized mice | 1 | 7.51 | 5.90 | 2.54 | 0.259 | 17000 |
human, average (± SD) | 1 | 2.74 (± 3.03) | 9.7 (± 4.4) | 2.90 (± 2.41) | 0.25 (± 0.26) | 13900 (± 3380) | |
literature | 16,000 (± 4,340) | ||||||
omeprazole | human, from humanized mice | 1 | 2.84 | 77.2 | 2020 | 52.2 | 229 |
human, average (± SD) | 1 | 2.59 (± 1.84) | 37.2 (± 26.9) | 1340 (± 513) | 40.9 (± 9.9) | 407 (± 216) | |
literature | 368 (± 250) | ||||||
metoprolol | human, from humanized mice | 1 | 1.65 | 174 | 105 | 46.5 | 1300 |
human, average (± SD) | 1 | 0.91 (± 0.48) | 200 (± 66) | 178 (± 110) | 55.9 (± 10.6) | 939 (± 347) | |
literature | 449 (± 303) | ||||||
midazolam | Human, from humanized mice | 1 | 2.37 | 62 | 475 | 31.7 | 53.5 |
Human, average (± SD) | 1 | 1.00 (± 0.82) | 71 (± 33) | 827 (± 352) | 41.5 (± 10.4) | 37.5 (± 17.4) | |
Literature | 23.7 (± 8.0) |